An interventional study of Augmented Reality Virtual Coach in Chronic Obstructive Pulmonary Disease (COPD) and Virtual Reality, sponsored by Groupe Hospitalier du Havre. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-23.
Sponsored by Groupe Hospitalier du Havre · Not applicable, Interventional, and Treatment
Among 10 studies in Pulmonary Disease, Chronic Obstructive by Groupe Hospitalier du Havre — 3 open to participants now, 3 under way, none of them phase 3. Pulmonary Disease, Chronic Obstructive · Groupe Hospitalier du Havre.
Among the 10 studies in Pulmonary Disease, Chronic Obstructive by Groupe Hospitalier du Havre, this one is one of 2 that started in 2026, is one of 5 with no phase, and was the 10th registered.
5,520 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.
This study's planned enrollment of 42 is below the median of 62 across 3,839 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Browse Pulmonary Disease, Chronic Obstructive studies →3 of the 10 studies in Pulmonary Disease, Chronic Obstructive by Groupe Hospitalier du Havre are open now, in 1 country. Each count lists the studies.
Of the 555 Pulmonary Disease, Chronic Obstructive studies recruiting now, 305 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 87 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →10 studies; the count open now beside each. This study's row is marked.
First in 2017; this study’s year is marked. 2 started in 2026.
Median enrollment 22 across the 5 interventional studies, 30 across the 5 observational. Of the 7 that completed or were terminated, 0 (0%) have results posted.
Groupe Hospitalier du Havre is the lead sponsor of 22 studies on the registry; 6 are open to participants now.
1 of the studies in Pulmonary Disease, Chronic Obstructive by Groupe Hospitalier du Havre that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07371754Groupe Hospitalier du HavreShear Wave Elastography of Intercostal Muscles for the Non-invasive Assessment of the Work of BreathinG | 2027-03-01 |
Among the 10 studies in Pulmonary Disease, Chronic Obstructive by Groupe Hospitalier du Havre, from their registry updates:
Nothing recorded among them since 2026-09-25.
Chronic obstructive pulmonary disease (COPD) is associated with dyspnea, reduced physical activity, muscle deconditioning, and impaired quality of life. Pulmonary rehabilitation is an effective non-pharmacological intervention, but access remains limited and long-term adherence to physical exercise is often difficult to maintain. Augmented reality may provide an innovative approach to support exercise practice by offering real-time visual and auditory guidance while allowing patients to remain anchored in their real environment.
The SPARK study is a multicenter, interventional, non-randomized, proof-of-concept study designed to assess the acceptability of an augmented reality virtual coach for physical exercise in adults with COPD. Participants will attend a single experimental session including baseline questionnaires, presentation of the augmented reality headset, a short immersive exercise session guided by a virtual coach, and post-immersion assessments. Acceptability will be evaluated using the Technology Acceptance Model 3 questionnaire before and after immersion. User experience will also be explored through focus group discussions analyzed according to UXive dimensions.
The study aims to determine whether this technology is acceptable to patients with COPD and to identify factors that may facilitate or limit its future integration into pulmonary rehabilitation pathways.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with chronic obstructive pulmonary disease will attend a single experimental session using an augmented reality headset with a virtual coach. After baseline questionnaires and headset presentation, participants will complete an approximately 20-minute guided exercise session including calf raises, sit-to-stand exercises, and stretching. The virtual coach provides standardized instructions and corrective feedback during strengthening exercises. Acceptability will be assessed before and after immersion using the TAM3 questionnaire, followed by a focus group exploring user experience.
Device: Augmented Reality Virtual Coach
Participants will use an augmented reality headset delivering a virtual coach-guided exercise session. The intervention consists of a single approximately 20-minute immersive session performed in a secured environment. The virtual coach provides standardized instructions and corrective feedback during strengthening exercises. The session includes calf raises, sit-to-stand exercises, and stretching. The intervention is designed to assess the acceptability and user experience of an augmented reality-based exercise support tool in adults with chronic obstructive pulmonary disease.
Also known as: Augmented Reality Exercise Coach, SPARK Virtual Coach
Global Acceptability Score of the Augmented Reality Virtual Coach
Acceptability will be assessed using the global score of the adapted Technology Acceptance Model 3 questionnaire completed immediately after the augmented reality immersion session. Items are rated on a 7-point Likert scale, with higher scores indicating greater acceptability. The mean global score will be compared with the theoretical neutral value of 4.
Time frame: Immediately after the augmented reality immersion session, during the single study visit
Plan to share: No
Started Jun 2026 (actual). Primary completion is estimated for Oct 2026, 4 months after the start.
Of 1,094 non-industry interventional studies with no phase under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 4 months is below that.
Counting every sponsor, half of 1,181 studies reached it within 22 months; a quarter within 10 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pulmonary Disease, Chronic Obstructive →
Groupe Hospitalier du Havre